Michael E. McFadden
Known title: Chief Executive OfficerCIK: 0001748333
Michael E. McFadden's purchase track record
Michael E. McFadden has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/13/2024 | ACOG | $15K | +1.1% | +19.5% | -1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACOG | ▲ Buy | Grant | 190,549 | $0 | 1/9/2026 | View on chart |
| ACOG | ▲ Buy | Open Market | 2,608 | $15K | 11/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Alpha Cognition Releases 180-Day Data on CONVERGE Program
Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.
Alpha Cognition Releases 180-Day Data on CONVERGE Program. Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.